Latest News

Announcing the UTCI Phase I Treatment Center

We would like to take this opportunity to introduce the opening of the UTCI Phase I Treatment Center.  The Center is housed on the 7th Floor of the Union Ave Office and will be staffed by Drs. Allen, Goorha, and Sachdev.  The Center has a dedicated research nurse and offers a complete line of service.

We are also very pleased to announce the opening of our first Phase I clinical trial:

 

A PHASE IB/II, MULTICENTER, TRIAL OF CVX-060, A SELECTIVE ANGIOPOIETIN-2 (ANG-2) BINDING, ANTI-ANGIOGENIC COVX-BODY, IN COMBINATION WITH SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

 

We are currently looking for potential participants for this study!

 

Appropriate candidates are those who:

- Have a histologically or cytologically confirmed
- advanced/metastatic solid tumor (does not have to be renal cell carcinoma) with measurable disease that is refractory to at least 1 line of systemic therapy
- Have ECOG PS of 0-1
- Do not have brain metastases
- Do not have any VEGF-related eligibility concerns

 

If you have a patient who you believe may be a good candidate, please send the patient's name and UTCI ID# to Debi Everts ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it ).

 

Please keep in mind that due to the unique nature of Phase I trials, we will require patients to be seen and evaluated by a member of the Phase I team prior to offering enrollment.  Selected patients will need to follow with a physician member of the Phase I team throughout the duration of their participation in the Phase I trial.  Referring physicians will be kept abreast of any clinical developments.

 

Thanks for your support and please do not hesitate to contact us if there are any questions!

The Phase I Team

 

Naruke Award Winner

The Tsuguo Naruke award for the best surgery paper at the 13th
World Conference on Lung Cancer (WCLC) was given to the paper
titled ”Objective review of surgeon reported lymph node dissection
after resection of lung cancer in a US metropolitan area” presented
by Drs. Mathew Ninan, James T. Wu, Jeffrey W. Allen, Aamer Farooq,
Kemp Kernstine and Raymond U. Osarogiagbon.


This paper was one of four presented by researchers from the University
of Tennessee Cancer Institute. Dr. Ninan presented this paper as the
Tsuguo Naruke lecture at the 13th World Conference on August 3, 2009.
The WCLC is the world’s most prestigious lung cancer conference,
run under the auspices of the International Association for the Study of
Lung Cancer (IASLC).


 

 

 

   

National Survey Lists Dr. Boston, Dr. Osarogiagbon and Dr. Yunus as the Regions Top Docs

 

 

Memphis Magazine’s
Top Docs 2009 - July Issue


 

Just what the
Doctor Ordered

Every great city demands great doctors.
Although adequate funding and state-of-
the-art facilities play an important role in
developing viable medical care, it is the
ingenuity and dedication of great medical
minds that truly raise the bar. In light of this,
we present a list of the top doctors in
Memphis. The following physicians have
dedicated their life's work to medical
research and/or treatment, and they offer
their services to patients all over the greater
Memphis area.

Barry Boston, MD
Gastrointestinal, Genitourinary & Prostate Cancer

Raymond Osarogiagbon, MD
Esophageal, Lung, & Gastrointestinal Cancer,
Sickle Cell Disease

Furhan Yunus, MD
Multiple Myeloma, Lymphoma

Dr. Furhan Yunus has called Memphis
home for the past 20 years. Born and
raised in Pakistan, he immigrated to the
U.S. “because I wanted to be in the best
medical system in the world.”

After receiving his medical training at the
University of Tennessee and the University
of Arizona, Yunus returned to Memphis,
where he is now chief medical officer of the
UT Cancer Institute (UTCI) and director of
the UT Blood and Marrow Transplant
Center. With almost 20 oncologists on
staff, UTCI is the largest adult cancer
service provider in the region, currently
handling some 5,000 new cancer patients
each year. The transplant center treats
hematological malignancies or cancers
of the bloodstream, such as leukemia and
lymphomas. A different division of UT is
responsible for solid organ transplants.

Over the years, Yunus has witnessed important changes in his field.

“Hematology, oncology, and transplantation are some of the fastest-changing subspecialties, because
of the huge amount of basic research and the increasing number of clinical trials,” he says. “In addition,
cancer research in general garners the largest share of the financial pie, and that has led to dramatic
advances in understanding the basic biology of cancer.”

The result is a significant improvement in the way cancers are now treated. “In the past 15 or 20 years,
we have gone from a very simplistic way of treating cancer by chemotherapy only, to giving patients
designer – or ‘smart’ – drugs that are genetically engineered, says Yunus. “The drugs are individually
tailored for each patient, so two lung cancer patients may get two completely different types of treatment.
And because they are individualized, based on the patient’s genetic makeup, they have little or no
side effects.”

These new treatments are also much more convenient for the patient. Instead of checking into a hospital
for several weeks of chemotherapy, patients can now take a pill at home, “just like taking a pill for high
blood pressure,” says Yunus.

He is cautiously optimistic about the future of cancer treatments. “We have been much more successful
at treating hematological cancers like leukemia. Even if we are not curing [the patients], we are at least
letting them live much longer than in the past. That is probably one of the most gratifying surprises, in terms
of the advances that science has made, and we have helped deliver those new treatments to patients here.”

He gives an example. Years ago, a patient diagnosed with multiple myeloma, a particularly aggressive
type of cancer, might live three years after diagnosis. “On average, most patients are living six or seven
years,” says Yunus, “and I have patients even living ten years or longer.”

Research on solid forms of cancer isn’t progressing quite as rapidly, but there is still hope.

“Science is working at a steady pace,” says Yunus. “Someday we can make cancer a chronic disease
instead of a fatal one.”

 

 

 

   

UTCI supports the Harrah's Hope House



UTCI SUPPORT: Recognized as a significant donor and supporter, The University of Tennessee Cancer Institute will participate in the ground breaking, April 22 for the American Cancer Society Harrah’s Hope Lodge at 718 Union Avenue. The facility will provide temporary housing for out-of-town cancer patients.

RENDERING COURTESY OF THE AMERICAN CANCER SOCIETY

Society Proceeds
With Hope Lodge


ERIC SMITH | The Daily News

Out-of-town cancer patients traveling to Memphis for chemotherapy or radiation treatments will soon have a free place to stay, giving them one less thing to worry about during their visits.


The Mid-South Division of the American Cancer Society on April 22 will break ground on the $8.5 million Harrah’s Hope Lodge, a 30,480-square-foot facility providing 40 private suites for adult cancer patients.


The three-story building will rise on 1.09 acres at 718 Union Ave., due east of Sun Studio at the northeast corner of Union and Marshall avenues in the medical district. ACS this week filed a $4.8 million permit application with the city-county Office of Construction Code Enforcement to build the facility.

Leighanne Hart, capital campaign director for the American Cancer Society, said the organization has raised 85 percent of the facility’s cost, the required milestone before the board of directors would give the green light to break ground.

Construction should start the first week of May and wrap up next summer.

Hart, who called the project her “heart and soul,” has been working on bringing a Hope Lodge here for about five years.

She said there is a huge need for this type of facility in Memphis.

“We receive calls in our office daily of people coming from out of town,” Hart said. “They have nowhere to stay and they’re calling us for help. Right now we have nothing.”

 

Just Like Home

Patients coming to the Lodge can stay free of charge as long as they’re receiving treatment at a local hospital or clinic. Admittance is granted on a first-come, first-served basis; it will be administered by an advisory group of physicians from hospitals and clinics throughout Shelby County.

The average length of stay at the lodges is five days to six weeks, Hart said, although she noted that a patient at the Nashville lodge once stayed 366 days while undergoing clinical trials at Vanderbilt Medical Center.

Vans will be available at the Lodge to shuttle patients to their appointments, or even on daily errands such as the drugstore or grocery store.

The facility’s first floor will have common areas such as kitchens, a living room, a library, patio and garden. The top two floors will have private rooms for patients and caregivers.

“We try to do everything we can to take care of the patient while they’re here,” Hart said.

The Harrah’s Hope Lodge will have a full-time live-in manager who is on call 24/7, a full-time and assistant manager during the day, a facilities manager, plus housekeeping staff and van drivers.